Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - betaxolol hydrochloride -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - betaxolol hydrochloride -

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

alcon laboratories australia pty ltd - betaxolol hydrochloride -

Kanada - angleščina - Health Canada

alcon canada inc - betaxolol (betaxolol hydrochloride) - liquid - 0.5% - betaxolol (betaxolol hydrochloride) 0.5% - beta-adrenergic agents

Kenija - angleščina - Pharmacy and Poisons Board

betaxolol hydrochloride - eye drops - 0.5%w/v - betaxolol

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - dorzolamide hydrochloride, quantity: 22.26 mg/ml (equivalent: dorzolamide, qty 20 mg/ml) - eye drops - excipient ingredients: water for injections; benzalkonium chloride; hyetellose; mannitol; sodium citrate dihydrate; sodium hydroxide - trusamide eye drops are indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

merck sharp & dohme llc - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - trusopt® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. trusopt is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1)] . risk summary there are no adequate and well-controlled studies in pregnant women with trusopt. dorzolamide caused fetal vertebral malformations when administered orally to rabbits at 2.5 mg/kg/day (37 times the clinical exposure). dorzolamide administered during the period of organogenesis was not teratogenic in rabbits dosed up to 1 mg/kg/day (15 times the clinical exposure). dorzolamide hydrochloride administered orally to rats during late gestation and lactation caused growth delays in offspring at 7.5 mg/kg/day (52 times the clinical exposure). growth was not delayed at 1 mg/kg/day (8.0 times the clinical exposure). the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general populati

Združene države Amerike - angleščina - NLM (National Library of Medicine)

alcon laboratories, inc. - pilocarpine hydrochloride (unii: 0ww6d218xj) (pilocarpine - unii:01mi4q9di3) - pilocarpine hydrochloride 10 mg in 1 ml - isopto® carpine is indicated for the:         none. pregnancy. category c. animal reproduction studies have not been conducted with pilocarpine hydrochloride. it is also not known whether pilocarpine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. isopto® carpine should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when isopto® carpine is administered to a nursing woman. safety and effectiveness of pilocarpine hydrochloride ophthalmic solution in pediatric patients have been established. no overall differences in safety or effectiveness have been observed between elderly and younger patients.

Združene države Amerike - angleščina - NLM (National Library of Medicine)

a-s medication solutions - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide 20 mg in 1 ml - dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. dorzolamide hydrochloride is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1) ]. teratogenic effects. pregnancy category c. developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of ≥ 2.5 mg/kg/day revealed malformations of the vertebral bodies. these malformations occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased fetal weights. no treatment-related malformations were seen at 1 mg/kg/day. these doses represent estimated plasma cmax levels in rabbits, 37 and 15 times higher than the lower limit of detection in human plasma following ocular administration, respectively. there are no adequate and well-controlled studies in pregnant women. dorzolamide hydrochloride should be used during pre

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

clinect pty ltd - apraclonidine hydrochloride, quantity: 5.75 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; sodium acetate; sodium chloride; hydrochloric acid; sodium hydroxide; purified water - to control intraocular pressure in glaucoma patients on maximally tolerated glaucoma therapy for a period of 3 months. in clinical studies the drop in intraocular pressure (iop) appeared to decrease after day 60 which may be associated with a progression of the disease or loss of effect of the drug. this phenomenon appears to be an individual occurence with a variable time of onset. as with any patient on maximally tolerated therapy (see dosage & administration), patients using apraclonidine 0.5% eye drops to delay surgery should have frequent follow-up examinations and treatment should be discontinued if iop rises significantly. in patients who have maintained a response to apraclonidine 0.5% eye drops for 3 months and a decision is made to continue treatment, safety aspects, including any evidence of corneal changes (see warnings and precautions), and iop control should be closely monitored.